Novartis sees PhIII success for Cushing's disease

Novartis says that SOM230 has proven to be the first drug to demonstrate efficacy in a late-stage study of Cushing's disease, a hormonal disorder in which adrenal glands produce potentially lethal levels of cortisol. The pharma company plans a regulatory filing later this year. "The study findings show that SOM230 has the potential to directly target the underlying pituitary tumor and suppress cortisol production, thereby helping patients achieve biochemical control of their Cushing's disease and the associated debilitating symptoms," said Annamaria Colao, one of the study investigators. Novartis release

Suggested Articles

Minerva's seltorexant helped patients fall asleep more quickly and stay asleep for longer, beating placebo and Sanofi’s Ambien in a phase 2b study.

Cannabidiol might work as a powerful antibiotic against certain drug-resistant bacteria such as methicillin-resistant S. aureus.

Krystal Biotech posted data from a phase 2 study showing its topical gene therapy closed the majority of wounds in patients with a rare skin disorder.